Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Things that seemed impossible, only a few years ago, are happening today. The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford.

Female clinician carrying out a treatment

The trial in Oxford is run by the STRONG research group of the Department of Paediatrics and the MDUK Oxford Neuromuscular Centre led by Professor Laurent Servais. Investigators, families, and the community are excited about the developments for Angelman syndrome in Oxford and look forward to seeing the results of the first of, hopefully, many more trials to come. This is the beginning of a new era for Angelman syndrome, where potential treatments targeting the root cause, the lack of functional UBE3A protein, are reaching the patients’ bedside. 

Angelman syndrome is a rare, genetic disorder, which affects the development of the nervous system. It results in severe developmental delay, balance issues, motor impairment and debilitating seizures.Some individuals with Angelman syndrome are unable to walk and most do not speak. It affects approximately 1 in 12,000 to 1 in 20,000 people globally. Most cases are not inherited, but instead occur spontaneously. With current practices, Angelman syndrome is not routinely detected before or at birth. At this time, there is no approved treatment and individuals are managed with non-specific medication to alleviate symptoms of Angelman syndrome. Affected individuals have a normal lifespan but never become independent adults. The diagnosis has a severe impact on family life, as these individuals need someone to care for them around the clock. Most caregivers must dedicate themselves to the care of their individual diagnosed with Angelman syndrome.

Read the full story on the Department of Paediatrics website

 

Similar stories

New evidence for how our brains handle surprise

A new study from the Bruno Group is challenging our perceptions of how the different regions of the cerebral cortex function. A group of ‘quiet’ cells in the somatosensory cortex that rarely respond to touch have been found to react mainly to surprising circumstances. The results suggest their function is not necessarily driven by touch, but may indicate an important and previously unidentified role across all the major cortices.

Language learning difficulties in children linked to brain differences

A new study using MRI has revealed structural brain changes in children with developmental language disorder (DLD), a common but under-recognised difficulty in language learning. Children with DLD aged 10-15 showed reduced levels of myelin in areas of the brain associated with speaking and listening to others, and areas involved in learning new skills. This finding is a significant advance in our understanding of DLD and these brain differences may explain the poorer language outcomes in this group.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.

New research reveals relationship between particular brain circuits and different aspects of mental wellbeing

Researchers at the University of Oxford have uncovered previously unknown details about how changes in the brain contribute to changes in wellbeing.

Night-time blood pressure assessment is found to be important in diagnosing hypertension

Around 15% of people aged 40-75 may have a form of undiagnosed high blood pressure (hypertension) that occurs only at night-time. Because they do not know about this, and therefore are not being treated for it, they are at a higher risk of cardiovascular disease such as stroke, heart failure, and even death, suggests new research from the University of Oxford published in the British Journal of General Practice.